/term/asset-impairment-charge/ROCO:6872 NaviFUS (ROCO:6872) Asset Impairment Charge
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Asset Impairment Charge

NaviFUS (ROCO:6872) Asset Impairment Charge : NT$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is NaviFUS Asset Impairment Charge?

NaviFUS's Asset Impairment Charge for the six months ended in Dec. 2023 was NT$0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.00 Mil.


NaviFUS Asset Impairment Charge Historical Data

The historical data trend for NaviFUS's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS Asset Impairment Charge Chart

NaviFUS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Impairment Charge
Get a 7-Day Free Trial - - - - -

NaviFUS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NaviFUS Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.00 Mil.


NaviFUS Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of NaviFUS's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


NaviFUS (ROCO:6872) Business Description

Traded in Other Exchanges
N/A
Address
No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103
NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS (ROCO:6872) Headlines

No Headlines